LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples

By LabMedica International staff writers
Posted on 27 Mar 2025
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)
Image: The study examined the influence of pre-analytical conditions on cell-free microRNA stability in blood plasma samples (Photo courtesy of 123RF)

Scientists worldwide are working to enhance the quality of diagnostics and prognosis for various diseases, including cancer, by analyzing different body fluids such as blood, urine, and saliva. MicroRNAs, which range from 18 to 25 nucleotides in length, are well-established post-transcriptional regulators of gene expression and play a crucial role in intracellular communication. These molecules, present in human biological fluids, are released from both normal and tumor cells, with about 3,000 individual microRNAs identified. These microRNAs circulate within biological fluids, often bound to biopolymers or packed into microvesicles, which makes them relatively stable. As a result, they are considered an ideal source of diagnostic material for liquid biopsies to detect tumors or other pathological conditions. For microRNAs to be utilized effectively as biomarkers, systematic and universally accepted guidelines for biosample processing must be developed, particularly concerning the stability of microRNAs during storage. Now, new research has shown that pre-analytical factors, such as the storage conditions of blood plasma or extracellular vesicles, significantly impact microRNA stability, thereby influencing the detected concentrations of specific microRNAs.

In a study conducted by researchers at the Novosibirsk Institute of Chemical Biology and Fundamental Medicine (ICBFM, Novosibirsk, Russia), the team investigated how different plasma storage conditions affected the stability of endogenous microRNAs in human blood plasma. The study focused on four endogenous microRNAs (miR-16, miR-19b, miR-23a, miR-451a) and the exogenous microRNA cel-miR-39, evaluating their stability under short- and long-term incubation at various temperatures. Additionally, the team examined how long-term storage affected the stability of microRNAs within extracellular vesicles (EVs). They also compared microRNA yields from fresh and archived plasma samples and assessed the impact of variations in miRNA extraction protocols and the use of RNA stabilizing agents on the efficiency of isolation.

The researchers employed a single-phase miRNA isolation method, which they had successfully used in previous studies to identify miRNA biomarkers for lung cancer in blood. Published in the ExRNA journal, the study confirmed that the degradation rate of microRNAs is influenced by their structure and packaging. They also found that adding various stabilization solutions to biofluids can impact the efficiency of miRNA extraction. The long-term findings from this study emphasize the importance of analyzing cell-free nucleic acids, including microRNAs, within 2 to 4 weeks after biological samples are collected to ensure the accuracy and reliability of diagnostic results.

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Silver Member
PCR Plates
Diamond Shell PCR Plates

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more